331 related articles for article (PubMed ID: 23393263)
1. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins.
Zanier K; Charbonnier S; Sidi AO; McEwen AG; Ferrario MG; Poussin-Courmontagne P; Cura V; Brimer N; Babah KO; Ansari T; Muller I; Stote RH; Cavarelli J; Vande Pol S; Travé G
Science; 2013 Feb; 339(6120):694-8. PubMed ID: 23393263
[TBL] [Abstract][Full Text] [Related]
2. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
3. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
[TBL] [Abstract][Full Text] [Related]
4. Association of papillomavirus E6 proteins with either MAML1 or E6AP clusters E6 proteins by structure, function, and evolutionary relatedness.
Brimer N; Drews CM; Vande Pol SB
PLoS Pathog; 2017 Dec; 13(12):e1006781. PubMed ID: 29281732
[TBL] [Abstract][Full Text] [Related]
5. Strategies for bacterial expression of protein-peptide complexes: application to solubilization of papillomavirus E6.
Sidi AO; Babah KO; Brimer N; Nominé Y; Romier C; Kieffer B; Pol SV; Travé G; Zanier K
Protein Expr Purif; 2011 Nov; 80(1):8-16. PubMed ID: 21777678
[TBL] [Abstract][Full Text] [Related]
6. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity.
Drews CM; Brimer N; Vande Pol SB
PLoS Pathog; 2020 Jan; 16(1):e1008295. PubMed ID: 31971989
[TBL] [Abstract][Full Text] [Related]
7. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
[TBL] [Abstract][Full Text] [Related]
8. Kinetic analysis of the interactions of human papillomavirus E6 oncoproteins with the ubiquitin ligase E6AP using surface plasmon resonance.
Zanier K; Charbonnier S; Baltzinger M; Nominé Y; Altschuh D; Travé G
J Mol Biol; 2005 Jun; 349(2):401-12. PubMed ID: 15890204
[TBL] [Abstract][Full Text] [Related]
9. Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
Stutz C; Reinz E; Honegger A; Bulkescher J; Schweizer J; Zanier K; Travé G; Lohrey C; Hoppe-Seyler K; Hoppe-Seyler F
PLoS One; 2015; 10(7):e0132339. PubMed ID: 26151636
[TBL] [Abstract][Full Text] [Related]
10. Papillomavirus E6 oncoproteins.
Vande Pol SB; Klingelhutz AJ
Virology; 2013 Oct; 445(1-2):115-37. PubMed ID: 23711382
[TBL] [Abstract][Full Text] [Related]
11. Activation of cap-dependent translation by mucosal human papillomavirus E6 proteins is dependent on the integrity of the LXXLL binding motif.
Spangle JM; Ghosh-Choudhury N; Munger K
J Virol; 2012 Jul; 86(14):7466-72. PubMed ID: 22553330
[TBL] [Abstract][Full Text] [Related]
12. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein.
Zhang Y; Dasgupta J; Ma RZ; Banks L; Thomas M; Chen XS
J Virol; 2007 Apr; 81(7):3618-26. PubMed ID: 17267502
[TBL] [Abstract][Full Text] [Related]
13. Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53.
Ansari T; Brimer N; Vande Pol SB
J Virol; 2012 Oct; 86(20):11386-91. PubMed ID: 22896608
[TBL] [Abstract][Full Text] [Related]
14. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.
Poirson J; Biquand E; Straub ML; Cassonnet P; Nominé Y; Jones L; van der Werf S; Travé G; Zanier K; Jacob Y; Demeret C; Masson M
FEBS J; 2017 Oct; 284(19):3171-3201. PubMed ID: 28786561
[TBL] [Abstract][Full Text] [Related]
15. Computational Analysis of Domains Vulnerable to HPV-16 E6 Oncoprotein and Corresponding Hot Spot Residues.
Malik RM; Fazal S; Kamal MA
Protein Pept Lett; 2021; 28(4):414-425. PubMed ID: 32703126
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand.
Ramirez J; Poirson J; Foltz C; Chebaro Y; Schrapp M; Meyer A; Bonetta A; Forster A; Jacob Y; Masson M; Deryckère F; Travé G
Angew Chem Int Ed Engl; 2015 Jun; 54(27):7958-62. PubMed ID: 26014966
[TBL] [Abstract][Full Text] [Related]
17. Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53.
Zanier K; ould M'hamed ould Sidi A; Boulade-Ladame C; Rybin V; Chappelle A; Atkinson A; Kieffer B; Travé G
Structure; 2012 Apr; 20(4):604-17. PubMed ID: 22483108
[TBL] [Abstract][Full Text] [Related]
18. Identification of a second transforming function in bovine papillomavirus type 1 E6 and the role of E6 interactions with paxillin, E6BP, and E6AP.
Das K; Bohl J; Vande Pol SB
J Virol; 2000 Jan; 74(2):812-6. PubMed ID: 10623743
[TBL] [Abstract][Full Text] [Related]
19. Benchtop holdup assay for quantitative affinity-based analysis of sequence determinants of protein-motif interactions.
Bonhoure A; Forster A; Babah KO; Gógl G; Eberling P; Kostmann C; Volkmer R; Tapia Mancilla V; Travé G; Nominé Y
Anal Biochem; 2020 Aug; 603():113772. PubMed ID: 32428443
[TBL] [Abstract][Full Text] [Related]
20. Design of a PDZbody, a bivalent binder of the E6 protein from human papillomavirus.
Karlsson OA; Ramirez J; Öberg D; Malmqvist T; Engström Å; Friberg M; Chi CN; Widersten M; Travé G; Nilsson MT; Jemth P
Sci Rep; 2015 Mar; 5():9382. PubMed ID: 25797137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
